Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pliant Therapeutics Inc
(NQ:
PLRX
)
15.70
+0.80 (+5.37%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pliant Therapeutics Inc
< Previous
1
2
3
4
Next >
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024
August 07, 2024
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
May 14, 2024
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis...
Via
Benzinga
These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
May 07, 2024
Via
Benzinga
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024
May 06, 2024
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?
February 05, 2024
Pliant Therapeutics reports 12-week interim data for bexotegrast in INTEGRIS-PSC Phase 2a trial. 320 mg group met primary and secondary endpoints, showing well-tolerance and reduction in liver...
Via
Benzinga
The Latest Analyst Ratings for Pliant Therapeutics
November 10, 2023
Via
Benzinga
Where Pliant Therapeutics Stands With Analysts
October 04, 2023
Via
Benzinga
Expert Ratings for Pliant Therapeutics
September 15, 2023
Via
Benzinga
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 05, 2024
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS...
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
February 05, 2024
Via
Benzinga
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday
September 27, 2023
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market...
Via
Benzinga
Where Pliant Therapeutics Stands With Analysts
August 22, 2023
Via
Benzinga
Expert Ratings for Pliant Therapeutics
May 18, 2023
Via
Benzinga
Recap: Pliant Therapeutics Q1 Earnings
May 09, 2023
Via
Benzinga
Pliant Therapeutics Reveals Encouraging Data From Liver Disease Trial
September 26, 2023
Pliant Therapeutics Inc (NASDAQ: PLRX) announced data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected
Via
Benzinga
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 26, 2023
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi...
Via
Benzinga
Why Shares of Pliant Therapeutics Are Rising Tuesday
September 26, 2023
The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.
Via
The Motley Fool
What 12 Analyst Ratings Have To Say About Pliant Therapeutics
May 02, 2023
Via
Benzinga
Pliant Therapeutics Shares Fall After Long-Term Data Of Bexotegrast In Lung Fibrosis Study
May 01, 2023
Via
Benzinga
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
September 26, 2023
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 26, 2023
Pre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors!
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
September 25, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
September 15, 2023
Friday's session saw 169 companies set new 52-week lows.
Via
Benzinga
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis – Could GRI-0621 Be The Solution?
August 31, 2023
Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 17, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
May 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
May 01, 2023
Via
Benzinga
First Republic Bank, Top Financial And Other Big Stocks Moving Lower On Monday
May 01, 2023
U.S. stocks traded lower, with the Nasdaq falling around 17 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
May 01, 2023
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.